Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the same period last
Outlook Therapeutics lost money this quarter, but lost less money than it did last year—that's progress. When a company is losing money, watching whether those losses get smaller over time helps you see if the business is moving in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.